Nucleophosmin1 and FLT3-ITD mutations in acute myeloid leukemia: Importance of conventional molecular technique in the era of targeted next-generation sequencing: A cross-sectional study from a tertiary care Centre in North India
Purpose: Nucleophosmin1 (NPM1) and FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) mutations influence the disease outcome in acute myeloid leukemia (AML). Newer molecular techniques, such as targeted next-generation sequencing (NGS), have better sensitivity and the ability to detect multiple mutations in a single run. However, their application is limited in resource-constrained setups. We aimed to analyze the prevalence of NPM1 and FTL3-ITD mutations in AML, vis-a-vis clinico-hematological characteristics, and compared conventional PCR with targeted NGS to detect FLT3-ITD mutations at diagnosis. Methods: Conventional and real-time PCR were performed on 130 AMLs to detect FLT3-ITD and NPM1 mutations (A, B, or D mutations), respectively. Sanger sequencing was performed on 21 NPM1 mutated AMLs for subtyping. Targeted NGS (Ion Torrent platform) was also performed on 20 random samples to detect FLT3-ITD mutations. Results: Fourteen (10.8%) patients had both mutations, 12 (9.2%) and 27 (20.8%) had isolated NPM1mutations and FLT3-ITD mutations, respectively. NPM1 mutant type A was detected in 90.5% (19/21) and type D in 9.5% (2/21) of patients. FLT3-ITD mutations were detected in 16 (31.3%) AML patients with recurrent cytogenetic abnormalities (AML-RCA) (p
Authors
- Jogeshwar Binota
- Riju Rani Deka
- Shano Naseem (ORCID: https://orcid.org/0000-0003-0580-019X)
- Pankaj Malhotra (ORCID: https://orcid.org/0000-0003-1198-8491)
- Prateek Bhatia (ORCID: https://orcid.org/0000-0001-6096-3587)
- Neelam Varma
Publication Details
- Journal
- International Journal of Pharmaceutical and Clinical Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.33545/26647591.2025.v7.i1a.122
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00